SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In the last few years, sodium-glucose cotransporter-2 (SGLT2) inhibitors, namely, empagliflozin, dapagliflozin, ipragliflozin, luseogliflozin, canagliflozin, and tofogliflozin, have demonstrated beneficial effects in T2DM patients with NAFLD.